Javara rides with Uber to reduce trial participation barriers
Javara is offering transportation for clinical trial participants via Uber Health, which enables patients to schedule prepaid rides up to 30 days in advance of site visits.
Archives for March 26, 2019
Evotec to discover and develop first-in-class oncology therapeutics in research tie-up
Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.
Science Exchange integrates WuXi LabNetwork into its marketplace
WuXi LabNetwork enters an agreement with Science Exchange enabling users to order compounds directly following an increased demand for specialty chemicals.
Cellesce scales organoid production for drug discovery using proprietary bioprocessing tech
Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
Sun Pharma receives Form 483 due to out-of-spec products
The India-based manufacturer receives a Form 483 from the US FDA after the agency noted the company failed to thoroughly review discrepancies.
AstraZeneca cuts 94 jobs from UK campus
The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.
Product loss mitigation through drying technology
Small molecule manufacturing can result in product loss, as the materials manufactured come into contact with internal surfaces thereby impacting drying and creating disruptions in efficency and cost-effectivness.
Applications of nanotech may provide bioavailability
Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drug’s chance of success, according to Ascendia CEO.
Digoxin API supply secured through acquisition
C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.